Skip to main content
TipRanks
Go Ultimate75% OFF

Electromedical Technologies (EMED) AI Stock Analysis

24 Followers
EMED

Electromedical Technologies

(Other OTC:EMED)

Select Model
Rating:34Underperform
Action:N/A
Date:11/13/24

The overall score for EMED reflects significant financial challenges, characterized by negative profitability and high leverage. Although there are no significant insights from technical analysis or earnings calls, the low valuation score due to ongoing losses and lack of dividends further impacts the stock's attractiveness. Improvements in cash flow management are noted but are insufficient to mitigate the broader financial instability.

Positive Factors
Revenue ModelThe diverse revenue model with direct sales, leasing, and subscriptions provides multiple income streams, enhancing financial resilience and adaptability to market changes.
Negative Factors
Negative ProfitabilityThe substantial negative profit margin reflects ongoing operational inefficiencies, which could hinder the company's ability to achieve sustainable profitability.

Electromedical Technologies (EMED) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap
$373.23K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.2
Beta (1Y)
38.89
Revenue Growth
-66.56%
EPS Growth
69.23%
Country
US
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Electromedical Technologies Business Overview & Revenue Model

Company Description

Electromedical Technologies, Inc. operates within the U.S. market, specializing in the creation and distribution of bioelectronic medical devices specifically designed for pain management. The company's primary product is WellnessPro Plus, a prescrip...

How the Company Makes Money

Electromedical Technologies generates revenue primarily through the sale of its bioelectronic devices directly to consumers, healthcare providers, and through distribution partnerships. The company's revenue model includes direct sales, leasing optio...

Electromedical Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

EMED against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NCELNCEL48Neutral$14.05M7.9121.75%―――
BJDXBJDX44Neutral$2.92M-0.11-113.80%――95.46%
EMEDEMED34Underperform$373.23K-0.2244.04%―-66.56%69.23%

* Healthcare Sector Average

Performance Comparison

-50%0%ERNANCELBJDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
EMED and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
EMEDElectromedical Technologies, Inc.―――
ERNAEterna Therapeutics Inc.1.68-36.07-95.55%
NCELNewcelx Ltd.2.61-0.87-25.00%
BJDXBluejay Diagnostics, Inc.2.61-20.27-88.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2024